#USA #New York #Class Action #Caribou Biosciences #CRBU

Caribou Biosciences Investors Alerted About Class Action Lawsuit

On February 21, 2025, renowned law firm Levi & Korsinsky, LLP announced a significant opportunity for investors in Caribou Biosciences, Inc. (NASDAQ: CRBU) regarding their involvement in a class action securities lawsuit. The firm is calling on affected investors to join the litigation process before the approaching deadline on February 24, 2025.

Overview of the Lawsuit

The class action lawsuit seeks to recover losses incurred by investors between July 14, 2023, and July 16, 2024. The complaint alleges that Caribou Biosciences misled investors through false statements regarding its product CB-010, which was claimed to be effective in treating patients with relapsed/refractory B-cell Non-Hodgkin Lymphoma (r/r B-NHL) and Large B-cell Lymphoma (LBCL).

Key Allegations

1. Overstated Safety and Efficacy: The lawsuit claims that Caribou overstated CB-010's safety and efficacy compared to existing autologous CAR-T therapies, which misled investors regarding its prospects and market position.
2. Financial Misrepresentation: The complaint further states that Caribou was at risk of running out of cash and lacked the necessary liquidity to sustain its operations, which could cripple its ongoing research activities surrounding the allogeneic CAR-NK platform.
3. Materially False Statements: It is asserted that the public statements made by the defendants were materially false and misleading, failing to disclose the financial and operational risks that posed a significant threat to the company.

What Affected Investors Should Do

Investors who believe they have suffered losses during the aforementioned time frame may reach out to Levi & Korsinsky, LLP to request appointment as lead plaintiff. It is important to note that participation does not require investors to fulfill this role to share in any potential recovery.

Interested parties can get in touch with Joseph E. Levi, Esq. at (212) 363-7500 or via email at email protected]. Alternatively, they can visit [Levi & Korsinsky’s website for more information.

No Financial Risk Involved

Moreover, joining this class action is without any financial risk to participants. Class members may qualify for compensation without incurring any out-of-pocket expenses, making it accessible for those impacted by the situation.

Why Choose Levi & Korsinsky

With over two decades of experience, the legal team at Levi & Korsinsky has successfully recovered hundreds of millions of dollars for shareholders across various high-stakes cases. Their extensive expertise in complex securities litigation has established the firm as one of the top securities litigation firms in the U.S., as recognized by ISS Securities Class Action Services.

Contact Information

For those wishing to find out more about the class action or who wish to discuss their situation with a representative from the firm, they can reach out to Levi & Korsinsky at their New York office:

• - Address: 33 Whitehall Street, 17th Floor, New York, NY 10004
• - Phone: (212) 363-7500
• - Email: [email protected]

Investors are encouraged to act quickly to ensure that they do not miss out on this opportunity to seek restitution for their losses in Caribou Biosciences.